As of 2026-01-18, the EV/EBITDA ratio of Sarepta Therapeutics Inc (SRPT) is -98.73. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SRPT's latest enterprise value is 2,636.28 mil USD. SRPT's TTM EBITDA according to its financial statements is -26.70 mil USD. Dividing these 2 quantities gives us the above SRPT EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 13.7x - 16.2x | 15.0x |
| Forward P/E multiples | 19.2x - 44.5x | 32.0x |
| Fair Price | (7.52) - 154.73 | 51.18 |
| Upside | -135.6% - 632.3% | 142.2% |
| Date | EV/EBITDA |
| 2026-01-15 | -99.43 |
| 2026-01-14 | -105.28 |
| 2026-01-13 | -100.02 |
| 2026-01-12 | -98.77 |
| 2026-01-09 | -109.32 |
| 2026-01-08 | -106.65 |
| 2026-01-07 | -107.87 |
| 2026-01-06 | -103.51 |
| 2026-01-05 | -98.49 |
| 2026-01-02 | -99.43 |
| 2025-12-31 | -100.26 |
| 2025-12-30 | -100.14 |
| 2025-12-29 | -101.43 |
| 2025-12-26 | -102.61 |
| 2025-12-24 | -103.40 |
| 2025-12-23 | -102.14 |
| 2025-12-22 | -99.12 |
| 2025-12-19 | -98.37 |
| 2025-12-18 | -95.63 |
| 2025-12-17 | -98.77 |
| 2025-12-16 | -103.36 |
| 2025-12-15 | -100.37 |
| 2025-12-12 | -100.30 |
| 2025-12-11 | -101.16 |
| 2025-12-10 | -102.93 |
| 2025-12-09 | -102.81 |
| 2025-12-08 | -101.59 |
| 2025-12-05 | -103.16 |
| 2025-12-04 | -105.36 |
| 2025-12-03 | -101.51 |
| 2025-12-02 | -96.14 |
| 2025-12-01 | -93.19 |
| 2025-11-28 | -99.55 |
| 2025-11-26 | -98.02 |
| 2025-11-25 | -91.74 |
| 2025-11-24 | -90.01 |
| 2025-11-21 | -85.23 |
| 2025-11-20 | -80.48 |
| 2025-11-19 | -80.12 |
| 2025-11-18 | -84.25 |
| 2025-11-17 | -84.64 |
| 2025-11-14 | -89.62 |
| 2025-11-13 | -85.74 |
| 2025-11-12 | -86.44 |
| 2025-11-11 | -86.36 |
| 2025-11-10 | -83.58 |
| 2025-11-07 | -84.99 |
| 2025-11-06 | -85.03 |
| 2025-11-05 | -89.07 |
| 2025-11-04 | -79.38 |